What is Anavex Life Sciences Book Value per Share?
Anavex Life Sciences's book value per share for the quarter that ended in Dec. 2023 was $1.65.
During the past 12 months, Anavex Life Sciences's average Book Value Per Share Growth Rate was -4.60% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 57.90% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 43.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Anavex Life Sciences was 227.10% per year. The lowest was -528.30% per year. And the median was 20.10% per year.
During the past 13 years, the highest P/B Ratio of Anavex Life Sciences was 28.41. The lowest was 0.00. And the median was 0.00.
Anavex Life Sciences Book Value per Share Historical Data
The historical data trend for Anavex Life Sciences's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Anavex Life Sciences's Book Value per Share
For the Biotechnology subindustry, Anavex Life Sciences's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anavex Life Sciences's PB Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Anavex Life Sciences's PB Ratio distribution charts can be found below:
* The bar in red indicates where Anavex Life Sciences's PB Ratio falls into.
Anavex Life Sciences Book Value per Share Calculation
Anavex Life Sciences's Book Value Per Share for the fiscal year that ended in Sep. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.
Anavex Life Sciences (NAS:AVXL) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Anavex Life Sciences Book Value per Share Related Terms
Thank you for viewing the detailed overview of Anavex Life Sciences's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Anavex Life Sciences (Anavex Life Sciences) Business Description
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its necessary compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AVXL has been successfully added to your 